How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
16
BHST Quote, Financials, Valuation and Earnings
Last price:
$4.9000
Seasonality move
:
-0.96%
Day range:
$4.8000 - $5.0300
52-week range:
$4.7287 - $12.8000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.55x
P/B ratio:
14.10x
Volume:
74.2K
Avg. volume:
41.6K
1-year change:
-3.05%
Market cap:
$109M
Revenue:
$25.2M
EPS (TTM):
-$0.69
Analysts' Opinion
-
Consensus RatingBioHarvest Sciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.6667, BioHarvest Sciences, Inc. has an estimated upside of 184.13% from its current price of $4.8100.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.0000 representing 100% downside risk from its current price of $4.8100.
Fair Value
-
According to the consensus of 2 analysts, BioHarvest Sciences, Inc. has 184.13% upside to fair value with a price target of $13.6667 per share.
BHST vs. S&P 500
-
Over the past 5 trading days, BioHarvest Sciences, Inc. has underperformed the S&P 500 by -6.94% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioHarvest Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioHarvest Sciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioHarvest Sciences, Inc. reported revenues of $9.1M.
Earnings Growth
-
BioHarvest Sciences, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter BioHarvest Sciences, Inc. reported earnings per share of -$0.14.
Enterprise value:
117.9M
EV / Invested capital:
--
Price / LTM sales:
2.55x
EV / EBIT:
--
EV / Revenue:
3.60x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-11.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$19.4M
Return On Assets:
-42.33%
Net Income Margin (TTM):
-36.33%
Return On Equity:
-733.31%
Return On Invested Capital:
-60.26%
Operating Margin:
-10.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $10.6M | $22.4M | $32.7M | $6.5M | $9.1M | |
| Gross Profit | $3.2M | $11.9M | $19.4M | $3.7M | $5.6M | |
| Operating Income | -$10M | -$7.9M | -$6.1M | -$2.1M | -$920K | |
| EBITDA | -$9.1M | -$6.7M | -$4.6M | -$1.8M | -$535K | |
| Diluted EPS | -$0.61 | -$1.20 | -$0.69 | -$0.16 | -$0.14 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.1M | $4.6M | $4.7M | $8M | $17.8M | |
| Total Assets | $12.4M | $9.6M | $10.6M | $25.8M | $35.2M | |
| Current Liabilities | $2.3M | $9.2M | $14.6M | $9.9M | $13.2M | |
| Total Liabilities | $8.5M | $13.1M | $18.3M | $21.7M | $27.5M | |
| Total Equity | $3.9M | -$3.5M | -$7.8M | $4.1M | $7.7M | |
| Total Debt | $6.1M | $3.8M | $3.7M | $11.8M | $16.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8M | -$7.3M | -$8M | -$1.8M | -$2.1M | |
| Cash From Investing | -$1.5M | -$2.9M | -$2.1M | -$470.3K | -$427.6K | |
| Cash From Financing | $8.8M | $11.3M | $18.5M | -$163.1K | $9.9M | |
| Free Cash Flow | -$9.5M | -$10M | -$10.1M | -$2.3M | -$2.5M | |
BHST
Sector
Market Cap
$109M
$112.3M
Price % of 52-Week High
37.58%
74.07%
Dividend Yield
0%
0%
Shareholder Yield
-3.96%
2.32%
1-Year Price Total Return
-3.05%
-3.05%
Beta (5-Year)
1.301
0.246
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.1425
200-day SMA
Sell
Level
$7.4036
Bollinger Bands (100)
Sell
Level
5.1906 - 10.0306
Chaikin Money Flow
Sell
Level
-693.8K
20-day SMA
Sell
Level
$5.1403
Relative Strength Index (RSI14)
Sell
Level
39.8409
ADX Line
Buy
Level
12.6059
Williams %R
Buy
Level
-99.2593
50-day SMA
Sell
Level
$5.5623
MACD (12, 26)
Sell
Level
-0.2000
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Sell
Level
-150.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.9072)
Sell
CA Score
(Annual)
Level (-5.3932)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (7.7787)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioHarvest Sciences, Inc. develops bio-cell growth platform technology. The firm engages in botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions. It offers nutraceutical health and wellness products, which includes dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients. The company was founded on April 19, 2013 and is headquartered in Vancouver, Canada.
Stock Forecast FAQ
In the current month, BHST has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BHST average analyst price target in the past 3 months is $13.6667.
-
Where Will BioHarvest Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioHarvest Sciences, Inc. share price will rise to $13.6667 per share over the next 12 months.
-
What Do Analysts Say About BioHarvest Sciences, Inc.?
Analysts are divided on their view about BioHarvest Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioHarvest Sciences, Inc. is a Sell and believe this share price will drop from its current level to $12.0000.
-
What Is BioHarvest Sciences, Inc.'s Price Target?
The price target for BioHarvest Sciences, Inc. over the next 1-year time period is forecast to be $13.6667 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BHST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioHarvest Sciences, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BHST?
You can purchase shares of BioHarvest Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioHarvest Sciences, Inc. shares.
-
What Is The BioHarvest Sciences, Inc. Share Price Today?
BioHarvest Sciences, Inc. was last trading at $4.9000 per share. This represents the most recent stock quote for BioHarvest Sciences, Inc.. Yesterday, BioHarvest Sciences, Inc. closed at $4.8100 per share.
-
How To Buy BioHarvest Sciences, Inc. Stock Online?
In order to purchase BioHarvest Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BHST Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BHST
Sector
P/E ratio
--
17.42x
PEG ratio
-0.02x
0.12x
P/B ratio
14.10x
1.48x
Price / LTM sales
2.55x
0.52x
Growth Metrics
BHST
Sector
Revenue growth
38.66%
2.79%
Earnings growth
7.03%
1.6%
Revenue (5-year growth)
158.55%
3.3%
Earnings forecast
-$0.10
$0.26
Profitability
BHST
Sector
Profitability FY 2024
$13.2M
$254.9M
Return on invested capital
-60.26%
4.29%
Return on assets
-42.33%
3.02%
Return on equity
-733.31%
7.5%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
12
Balance Sheet
BHST
Sector
Total cash
$11M
$85.8M
Short term investments
--
$31.1M
Total assets
$25M
$1B
Long term debt
$16.1M
$5.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 43x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 43x
Alerts
Sell
49
HYMC alert for Feb 3
Hycroft Mining Holding Corp. [HYMC] is up 7.64% over the past day.
Buy
67
FBRX alert for Feb 3
Forte Biosciences, Inc. [FBRX] is down 1.74% over the past day.
Buy
72
BNR alert for Feb 3
Burning Rock Biotech Ltd. [BNR] is down 4.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
